Altheia Science — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Altheia Science is a private, Milan-based biotech focused on developing curative cell and gene therapies for autoimmune diseases. Founded in 2018, the company appears to be in a pre-clinical or early research stage, building its therapeutic platform. While the provided data mentions AI-powered digital pathology for cancer, the website content strongly emphasizes a pivot towards autoimmune disease therapeutics, indicating a strategic focus on this high-need area. Key details on leadership, pipeline specifics, and funding remain unclear from the available information.

Autoimmune Diseases

Technology Platform

Cell and gene therapy platform for immune system reprogramming (specifics undisclosed).

Opportunities

The global autoimmune disease treatment market is large and relies on chronic therapies.

A curative, one-time cell or gene therapy could capture significant value and transform patient care.

Advances in cell engineering and manufacturing from the oncology field provide a roadmap for development.

Risk Factors

High scientific risk in developing a safe and effective curative therapy for complex autoimmune disorders.

Heavy reliance on future fundraising in a competitive capital environment.

Intense and growing competition from larger, well-resourced biopharma companies in the same therapeutic space.

Competitive Landscape

The field of cell and gene therapy for autoimmunity is emerging but competitive. Companies like Sangamo (with GSK), Kyverna Therapeutics, Cabaletta Bio, and Sonoma Biotherapeutics are advancing various engineered cell therapy approaches. Large pharma (e.g., Novartis, Bristol Myers Squibb) are also active through internal programs and partnerships.

More companies in RNA Therapeutics (non-mRNA) →More companies in Italy →